

Regulated information

Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA

Gosselies, Belgium, 17 February 2015 - BONE THERAPEUTICS, a leader in bone cell therapy addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces it has received notifications of shareholding from various parties: S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA in accordance with the Belgian Law of 2 May 2007 concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market.

Shareholders holding more than 10% of the shares of the Company:

- S.R.I.W. (Société Régional d'Investissement de Wallonie) and its subsidiary Sofipôle (Société Wallonne pour le Financement des Infrastructures des Poles de Compétitivité), hold together 765,936 shares or 11.7% of the 6,547,779 outstanding shares of the Company at the time of notification.

Shareholders holding more than 5% of the shares of the Company:

- Mr J. Reymann holds 546,710 shares or 8.35% of the 6,547,779 outstanding shares of the Company at the time of notification;
- SFPI SA (Société Fédérale de Participations et d'Investissement) holds 416,406 shares or 6.36% of the 6,547,779 outstanding shares at the time of notification;
- Theodorus II SA (the seed fund of the Université Libre de Bruxelles – ULB) holds 401,610 shares or 6.13% of the 6,547,779 outstanding shares of the Company at the time of notification.

Full versions of all transparency notifications are available on the website of Bone Therapeutics, under the heading [Investors](#).

-Ends-

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair and fracture prevention. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.

PREOB[®], Bone Therapeutics' autologous bone cell product, is currently in pivotal Phase IIb/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB[®], its allogeneic "off-the-shelf" bone cell product, is in Phase II for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs and develops novel product candidates.

Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics' regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 9 patent families. Further information is available at www.bonetherapeutics.com.

For more information, please contact:

Bone Therapeutics SA

Tel: +32 (0)2 529 59 90

Enrico Bastianelli, Chief Executive Officer/ Wim Goemaere, Chief Financial Officer

investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries

Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Amber Bielecka, Mary-Jane Elliott, Jessica Hodgson and Lindsey Neville

Bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries

NewCap Investor Relations & Financial Communications

Tel: + 33 (0)1 44 71 94 94

Pierre Laurent and Antoine Denry

bone@newcap.fr

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.